||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
GlaxoSmithKline Share Discussion Threads
Showing 13876 to 13898 of 13900 messages
|Nice chart bracke.|
|I bought at 1405 and plan to keep these - but I may take out a small s at 1700 as a wee hedge.|
|Well it's going up on this leg, 1715p will be difficult to get through, so could retrace to around 1645p imho but I don't really sell at resistance, just hold and add more on any retrace.|
Gold star for you. maurillac missed 'sideways'.
Worth keeping an eye on the price action if you are thinking of a, I'll say it quietly, short.|
|Nah it may go up or down or sideways :)|
|so it could go up or down, or up, down and up again ;)
|Having reached the Median Line (middle green) it's decision time. Best option is 'zoom' through and keep going. Second best is move above ML then drop back for a successful retest. Third best is as second best but test fails to hold. Equal third, fails to break above ML and simply retraces.
I suppose I should mention the possibility that the share price simply tracks up along the ML.
|Courtesy of Rowan Dartington:
GlaxoSmithKline (GSK.L) Buy Income Risk 3
The Pharmaceuticals company recently announced Final results to December 2016. The results were in line with expectations with Group sales rising +17% to £27.9bn (+5% constant exchange rates), aided by a weak Sterling and growth in new products. In terms of outlook, 2017 Group EPS will depend on the timing and degree of the impact of US generic competition on Glaxo's asthma drug, Advair. Assuming a bearish case for Advair (assumes US Advair sales fall -45% to $1.36bn in 2017), core EPS will be flattish if competition begins mid-year Valuing the Group on a Dec’17 P/E of 14.5x, an 11% discount to the Market. This is good value considering that the Pharmaceutical division should not be impacted significantly by generics for several years post 2017. Total Pharmaceutical sales should be slightly higher in 2020 compared to 2016 due to new products (+£2.2bn to £6bn by 2020) outweighing the decline in US Advair sales (c £1.3bn in total). The two other divisions, Vaccines and Consumer Healthcare, should continue to trade well on the back of the Novartis acquisitions. The Group is trading at a discount to its Global Consumer Healthcare peers who trade on an average P/E of around 20x. The yield of 5% should also offer great protec-tion in these uncertain equity markets. Trump should not impact the pharmaceutical sector too much because competition has worked well in terms of the patent rules and of the strength of the Pharmacy Benefit Managers.|
|Onwards to 1715p resistance, within a rising trend channel|
|No, what is it, buy/sell?|
|Hi there, did anybody notice the 1,351,062 trade at 16.39|
|With the £ heading lower, who knows, it's possible, it's just one of a few that have been earmarked before, the low £ allows a pedestrian to make a blow out offer, therefore likely to meet approval of shareholders..interesting times ahead.|
|Unilever today, will glaxo be next...?|
|Figures, also defensive qualities when the markets correct.
Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target|
|17th feb Jefferies buy tp 1800p up from 1780p|
|Tks, I must if been thinking of another stock.|
|XD,Next Thursday 23th Feb 23p per share.Paid on Thursday 13th of April.|
|Isn't it ex div today?|
Next stop £17, or maybe a pause at 16.50?|
|NY Boy - Seems to be doing well, I'm happy with the ViiV statement, good start for new CEO, but things can change haha.|
|Broken through 1592p resistance, closes above this level, suggest a crack at next resistance level 1715p this quarter.|